Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
出版年份 2018 全文链接
标题
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
作者
关键词
HIV-1, Integrase, Infectivity, Potency, Susceptibility, Modeling, Resistance
出版物
Retrovirology
Volume 15, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-05-16
DOI
10.1186/s12977-018-0420-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors
- (2018) Tomokazu Yoshinaga et al. ANTIVIRAL RESEARCH
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
- (2017) Joel E. Gallant et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
- (2017) Xue Zhi Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome
- (2017) Dario Oliveira Passos et al. SCIENCE
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
- (2017) Paul E Sax et al. Lancet HIV
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
- (2016) Xue Zhi Zhao et al. ACS Chemical Biology
- Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC
- (2016) Seble G. Kassaye et al. CLINICAL INFECTIOUS DISEASES
- Drug resistant integrase mutants cause aberrant HIV integrations
- (2016) Janani Varadarajan et al. Retrovirology
- Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants
- (2016) Steven J. Smith et al. Retrovirology
- Will drug resistance against dolutegravir in initial therapy ever occur?
- (2015) Mark A. Wainberg et al. Frontiers in Pharmacology
- Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
- (2014) Tomokazu Yoshinaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
- (2014) T. Mesplede et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
- (2014) Xue Zhi Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
- (2014) Xue Zhi Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase
- (2013) Peter K. Quashie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- What if HIV were unable to develop resistance against a new therapeutic agent?
- (2013) Mark A Wainberg et al. BMC Medicine
- Dolutegravir: First Global Approval
- (2013) Anita D. Ballantyne et al. DRUGS
- Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744)
- (2013) Brian A. Johns et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV
- (2013) Bhavik M. Shah et al. PHARMACOTHERAPY
- Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations
- (2013) Janani Varadarajan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- MK-0536 Inhibits HIV-1 Integrases Resistant to Raltegravir
- (2011) Mathieu Métifiot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
- (2011) Nicolas A. Margot et al. ANTIVIRAL RESEARCH
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Retroviral intasome assembly and inhibition of DNA strand transfer
- (2010) Stephen Hare et al. NATURE
- Resistance to Integrase Inhibitors
- (2010) Mathieu Métifiot et al. Viruses-Basel
- Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
- (2009) S. Fransen et al. JOURNAL OF VIROLOGY
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro
- (2008) I. Malet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
- (2008) O. Goethals et al. JOURNAL OF VIROLOGY
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now